Novavax Inc. is exploring its options in creating a Zika virus vaccine candidate.
So far, the Gaithersburg vaccine maker (NASDAQ: NVAX) has been mum about whether it would join other Greater Washington companies in the race to stop the Zika virus. The disease has caused concern among worldwide health leaders in recent months because of a suspected connection to birth defects in newborns and Guillain-Barré syndrome in adults.
{iframe}http://www.bizjournals.com/washington/morning_call/2016/03/novavax-exploring-options-with-zika-virus-vaccine.html?ana=e_wash_rdup&s=newsletter&ed=2016-03-01&u=wjGEy67ABoSnsLErlc5ry0j5hx3&t=1456846809{/iframe}